{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91"}]}],"title":"Baseline Platelet counts >= 30 Gi/L,"},{"categories":[{"measurements":[{"groupId":"OG000","value":"42"}]}],"title":"Baseline Platelet counts >= 50 Gi/L,"},{"categories":[{"measurements":[{"groupId":"OG000","value":"276"}]}],"title":"Maximum Platelet Count >= 30 Gi/L"},{"categories":[{"measurements":[{"groupId":"OG000","value":"259"}]}],"title":"Maximum Platelet Count >= 50 Gi/L"}],"denoms":[{"counts":[{"groupId":"OG000","value":"302"}],"units":"Participants"}],"description":"Subjects who achieved maximum platelet count at least once during treatment. All platelet counts after an on-study splenectomy are not classed as responses.\n\nPlatelet counts within 7 days after a platelet transfusion are not classed as responses.\n\nPlatelet counts while taking an increased ITP medication or within 6 weeks after the end of an increased ITP medication are not classed as responses.","groups":[{"description":"Open-label eltrombopag was supplied in 25, 50, 75 mg tablets. All subjects started at 50mg once daily and dose was increased or decreased based on platelet count (target range 50-200Gi/L). Alternate days and interruption of dosing was permitted to maintain target range of platelet count. Doses could range from 25 to 75mg. Subjects could remain on treatment up to 2 years.","id":"OG000","title":"Eltrombopag"}],"paramType":"NUMBER","populationDescription":"ITT population","reportingStatus":"POSTED","timeFrame":"Baseline up to 2 years","title":"Subjects Achieving Maximum Platelet Counts Greater Than or Equal to 30 Gi/L or 50 Gi/L in the Absence of Rescue Medication","type":"SECONDARY","unitOfMeasure":"Participants"}